See Article, pages 1237–1245
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Non-alcoholic steatohepatitis drug development pipeline: an update.Semin Liver Dis. 2022 Aug; 42: 379-400
- Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort.Hepatology. 2016; 64: 1969-1977
- Pathogenesis of NASH: the impact of multiple pathways.Curr Hepatol Rep. 2018; 17: 350-360
- Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies.Clin Gastroenterol Hepatol. 2022 Aug 4;
- Prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med. 2021; 385: 1559-1569
- Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Gastroenterology. 2020; 158: 1611-1625 e12
- Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol. 2018; 69: 406-460
- Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration.Hepatology. 2021; 73: 2023-2027
- Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis.Clin Gastroenterol Hepatol. 2019; 17: 616-629 e26
- Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.Hepatology. 2022; 75: 1647-1661
- The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.Hepatology. 2019; 70: 1913-1927
- Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials.J Hepatol. 2020; 73: 26-39
- Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension.Gastroenterology. 2020; 158: 1334-1345 e5
- Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.J Hepatol. 2021; 74: 274-282
- Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.J Hepatol. 2022 Nov; 77 (Epub 2022 Jul 16): 1237-1245
- STELLAR 3 and STELLAR 4: lessons from the fall of Icarus.J Hepatol. 2020; 73: 9-11
Article info
Publication history
Published online: October 31, 2022
Accepted:
October 21,
2022
Received in revised form:
October 18,
2022
Received:
September 7,
2022
Identification
Copyright
© 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
